Galera to Present at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting

September 26, 2022

https://www.globenewswire.com/news-release/2022/09/26/2522373/0/en/Galera-to-Present-at-2022-American-Society-for-Radiation-Oncology-ASTRO-Annual-Meeting.html

MALVERN, Pa., Sept. 26, 2022 (GLOBE NEWSWIRE) — Galera Therapeutics, Inc. (Nasdaq:GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that tumor outcomes data from its Phase 3 ROMAN trial of avasopasem for severe oral mucositis (SOM) and final data from its Phase 2 AESOP trial of avasopasem for chemoradiotherapy-induced esophagitis will be highlighted in two presentations at the upcoming 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting, taking place October 23-26, 2022 in San Antonio, Texas. Additionally, poster presentations will highlight the Phase 2 EUSOM trial of avasopasem for SOM in Europe and the ongoing GRECO-1 trial of rucosopasem for non-small cell lung cancer.

Read more at globenewswire.com

Related news for (GRTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.